Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

68.25USD
1:30am IST
Change (% chg)

$-0.07 (-0.10%)
Prev Close
$68.32
Open
$68.50
Day's High
$68.95
Day's Low
$68.00
Volume
1,952,710
Avg. Vol
1,966,906
52-wk High
$100.23
52-wk Low
$65.06

Latest Key Developments (Source: Significant Developments)

AbbVie Says Entered Term Loan Credit Agreement
Wednesday, 17 Jul 2019 

July 16 (Reuters) - AbbVie Inc ::ABBVIE SAYS ENTERED TERM LOAN CREDIT AGREEMENT.ABBVIE - AGREEMENT PROVIDES UNSECURED TERM LOAN FINANCING CONSISTING OF A $1.5 BILLION 364-DAY TERM LOAN TRANCHE.ABBVIE - AGREEMENT PROVIDES UNSECURED TERM LOAN FINANCING CONSISTING OF A $2.5 BILLION 3-YEAR TERM LOAN TRANCHE.ABBVIE - AGREEMENT ALSO PROVIDES UNSECURED TERM LOAN FINANCING CONSISTING OF A $2.0 BILLION 5-YEAR TERM LOAN TRANCHE.  Full Article

Elliott management advocated for an Allergan split prior to sale - Bloomberg Reporter Tweet
Wednesday, 26 Jun 2019 

June 26 (Reuters) - :ELLIOTT HAD BUILT STAKE IN ALLERGAN WAS ADVOCATING FOR BREAK UP OF CO PRIOR TO IT ANNOUNCING PLANS TO BE ACQUIRED BY ABBVIE - BLOOMBERG REPORTER TWEET.  Full Article

AbbVie Believes It Is Unlikely There Will Be A Botox Biosimilar For A Long Time - Conf. Call
Tuesday, 25 Jun 2019 

June 25 (Reuters) - AbbVie Inc ::ABBVIE INC EXECUTIVE SAYS ASSETS OF THE QUALITY OF ALLERGAN ARE NOT ALWAYS AVAILABLE AND NOT CERTAINLY AT THIS VALUE: CONF. CALL.ABBVIE CEO SAYS BELIEVES IT IS HIGHLY UNLIKELY THERE WILL BE A BOTOX BIOSIMILAR FOR A LONG TIME.ABBVIE CEO SAYS FEELS COMFORTABLE WITH RISK RELATED TO ALLERGAN'S OPIOID EXPOSURE.ABBVIE CEO SAYS ALLERGAN BREAKUP FEE IS 1% FOR ALLERGAN, 2% FOR ABBVIE : CONF. CALL.ABBVIE EXECUTIVE SAYS NOT BUILDING IN A LARGE CONTRIBUTION FROM ALLERGAN'S PIPELINE INTO ITS PROJECTIONS.  Full Article

Abbvie To Acquire Allergan For $63 Bln
Tuesday, 25 Jun 2019 

June 25 (Reuters) - AbbVie Inc ::ABBVIE TO ACQUIRE ALLERGAN IN TRANSFORMATIVE MOVE FOR BOTH COMPANIES.TRANSACTION EQUITY VALUE OF APPROXIMATELY $63 BILLION.ALLERGAN SHAREHOLDERS WILL RECEIVE 0.8660 ABBVIE SHARES AND $120.30 IN CASH FOR EACH ALLERGAN SHARE, FOR A TOTAL CONSIDERATION OF $188.24 PER ALLERGAN SHARE.UPON COMPLETION OF TRANSACTION, ABBVIE WILL CONTINUE TO BE INCORPORATED IN DELAWARE AS ABBVIE INC.DEAL IS EXPECTED TO BE 10% ACCRETIVE TO ADJUSTED EARNINGS PER SHARE OVER FIRST FULL YEAR FOLLOWING CLOSE OF TRANSACTION.ABBVIE WILL CONTINUE TO BE LED BY RICHARD A. GONZALEZ AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER.EXPECTED TO GENERATE SIGNIFICANT ANNUAL OPERATING CASH FLOW, WHICH WILL SUPPORT A DEBT REDUCTION TARGET OF $15 TO $18 BILLION BEFORE END OF 2021.ABBVIE ANTICIPATES THAT ACQUISITION WILL PROVIDE ANNUAL PRE-TAX SYNERGIES AND OTHER COST REDUCTIONS OF AT LEAST $2 BILLION IN YEAR THREE.ABBVIE WILL CONTINUE TO BE INCORPORATED IN DELAWARE AS ABBVIE INC. AND HAVE ITS PRINCIPAL EXECUTIVE OFFICES IN NORTH CHICAGO, ILL.2 MEMBERS OF ALLERGAN'S BOARD, INCLUDING CHAIRMAN AND CHIEF EXECUTIVE OFFICER, BRENT SAUNDERS, WILL JOIN ABBVIE'S BOARD UPON CLOSE OF DEAL.COMBINED CO WILL PRODUCE ROBUST CASH FLOW TO SUPPORT CONTINUED DIVIDEND GROWTH, FURTHER INVESTMENT IN PIPELINE AND REDUCTION OF DEBT LEVELS.AFTER DEAL CLOSE, CO'S SHAREHOLDERS TO OWN ABOUT 83% OF CO AND ALLERGAN SHAREHOLDERS WILL OWN ABOUT 17% OF ABBVIE.  Full Article

Abbvie Nears Deal To Buy Allergan For More Than $60 Bln - WSJ
Tuesday, 25 Jun 2019 

June 25 (Reuters) - :ABBVIE NEARS DEAL TO BUY ALLERGAN FOR MORE THAN $60 BILLION - WSJ.ABBVIE'S ALLERGAN TAKEOVER, WORTH $188 A SHARE IN CASH AND STOCK, IS EXPECTED TO BE ANNOUNCED LATER TUESDAY - WSJ, CITING SOURCES.  Full Article

Abbvie Announces USFDA Lifts Partial Clinical Hold On Phase 3 Study Of Venetoclax
Monday, 24 Jun 2019 

June 24 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES US FDA LIFTS PARTIAL CLINICAL HOLD ON PHASE 3 STUDY OF VENETOCLAX IN PATIENTS WITH MULTIPLE MYELOMA POSITIVE FOR THE T(11;14) GENETIC ABNORMALITY.ABBVIE INC - FDA REMOVED PARTIAL CLINICAL HOLD BASED UPON AGREEMENT ON REVISIONS TO CANOVA STUDY PROTOCOL.ABBVIE INC - REVISIONS TO STUDY INCLUDE NEW RISK MITIGATION MEASURES, PROTOCOL-SPECIFIED GUIDELINES AND UPDATED FUTILITY CRITERIA.ABBVIE INC - ALL OTHER CLINICAL TRIALS EVALUATING VENETOCLAX IN PATIENTS WITH MULTIPLE MYELOMA REMAIN ON PARTIAL CLINICAL HOLD.ABBVIE INC - PARTIAL CLINICAL HOLD DOES NOT IMPACT ANY OF APPROVED INDICATIONS FOR VENETOCLAX.  Full Article

AbbVie Sets Quarterly Cash Dividend Of $1.07 Per Share
Thursday, 20 Jun 2019 

June 20 (Reuters) - AbbVie Inc ::SETS QUARTERLY CASH DIVIDEND OF $1.07 PER SHARE.  Full Article

Bristol-Myers Presents Updated Data From Mid-Stage Trial Of Empliciti Plus Pomalidomide And Dexamethasone In Multiple Myeloma
Friday, 14 Jun 2019 

June 14 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB PRESENTS UPDATED EFFICACY DATA FROM PHASE 2 TRIAL OF EMPLICITI (ELOTUZUMAB) PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM).BRISTOL-MYERS SQUIBB CO - EMPLICITI-BASED COMBINATION SHOWED IMPROVEMENTS ACROSS EFFICACY ENDPOINTS.BRISTOL-MYERS SQUIBB CO - EMPLICITI-BASED COMBINATION SHOWED IMPROVEMENTS ACROSS EFFICACY ENDPOINTS.BRISTOL-MYERS - IN DESCRIPTIVE ANALYSIS, ADDITION OF EMPLICITI TO POMALIDOMIDE AND DEXAMETHASONE REDUCED RISK OF DEATH BY 46% AMONG PATIENTS WITH RRMM.BRISTOL-MYERS SQUIBB CO - SAFETY RESULTS FOR EPD WERE CONSISTENT WITH PRIMARY ANALYSIS AND WITH PRIOR FINDINGS FOR EMPLICITI AND POMALIDOMIDE REGIMENS.BRISTOL-MYERS SQUIBB - PATIENTS TREATED WITH EPD CONTINUED TO EXPERIENCE SUSTAINED & CLINICALLY RELEVANT OS AND PFS BENEFITS VERSUS PATIENTS TREATED WITH PD.  Full Article

AbbVie reaches agreement with pan-Canadian Pharmaceutical Alliance for Venclexta
Thursday, 23 May 2019 

May 23 (Reuters) - AbbVie Inc ::ABBVIE REACHES AN AGREEMENT WITH THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE (PCPA) FOR VENCLEXTA®, A TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).ABBVIE INC - FOLLOWING SIGNING OF AN AGREEMENT ONTARIO IS FIRST PROVINCE TO REIMBURSE VENCLEXTA..ABBVIE INC - VENCLEXTA MONOTHERAPY WILL BE AVAILABLE THROUGH EXCEPTIONAL ACCESS PROGRAM.  Full Article

Abbvie Launches Orilissa (Elagolix) 200 Mg Bid Dose For The Treatment Of Moderate To Severe Pain Associated With Endometriosis
Tuesday, 21 May 2019 

May 21 (Reuters) - AbbVie Inc ::ABBVIE LAUNCHES ORILISSA (ELAGOLIX) 200 MG BID DOSE FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS.ABBVIE INC - 7 OUT OF 10 WOMEN BEING MANAGED FOR ENDOMETRIOSIS HAVE UNRESOLVED PAIN THROUGHOUT MONTH.ABBVIE INC - ORILISSA (ELAGOLIX) 200 MG TWICE DAILY IS NOW AVAILABLE.  Full Article

RPT-BUZZ-U.S. stocks weekly: Not half bad

(Repeats from Friday. Updates chart) ** S&P 500 snaps 3-week winning streak, slips 0.3% as all eyes are on G20 Summit. Though index finishes first half up 17.3%, the best start to a year since 1997 ** That said, charts suggest risk the SPX may have a bumpy ride ahead ** And while the DJI may still see another push , the Nasdaq's high hurdles may be too high ** This as lagging small caps may loom large ** Most sectors decline: Real estate and utilities fall most, while fin